Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Claudia Pontillo; Zhen-Yu Zhang; Joost P. Schanstra; Lotte Jacobs; Petra Zuerbig; Lutgarde Thijs; Adela Ramirez-Torres; Hiddo J. L. Heerspink; Morten Lindhardt; Ronald Klein; Trevor Orchard; Massimo Porta; Rudolf W. Bilous; Nishi Charturvedi; Peter Rossing; Antonia Vlahou; Eva Schepers; Griet Glorieux; William Mullen; Christian Delles; Peter Verhamme; Raymond Vanholder; Jan A. Staessen; Harald Mischak; Joachim Jankowski

doi:10.1016/j.ekir.2017.06.004

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Claudia Pontillo
, Zhen-Yu Zhang
, Joost P. Schanstra
, Lotte Jacobs
, Petra Zuerbig
, Lutgarde Thijs
, Adela Ramirez-Torres
, Hiddo J. L. Heerspink
, Morten Lindhardt
, Ronald Klein
, Trevor Orchard
, Massimo Porta
, Rudolf W. Bilous
, Nishi Charturvedi
, Peter Rossing
, Antonia Vlahou
, Eva Schepers
, Griet Glorieux
, William Mullen
, Christian Delles

Peter Verhamme, Raymond Vanholder, Jan A. Staessen^*, Harald Mischak, Joachim Jankowski

^*Corresponding author for this work

Pathologie

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to

Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.

Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P <0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P

Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.

Original language	English
Pages (from-to)	1066-1075
Number of pages	10
Journal	Kidney International Reports
Volume	2
Issue number	6
DOIs	https://doi.org/10.1016/j.ekir.2017.06.004
Publication status	Published - Nov 2017

Keywords

biomarker
chronic kidney disease
clinical science
glomerular filtration rate
peptidomics
proteomics
GLOMERULAR-FILTRATION-RATE
PROGRESSION
FIBROSIS
TRIAL
RECLASSIFICATION
MICROALBUMINURIA
CANDESARTAN
RETINOPATHY
PREVENTION
FIBRINOGEN

Access to Document

10.1016/j.ekir.2017.06.004Licence: CC BY-NC-ND

Cite this

Pontillo, C., Zhang, Z.-Y., Schanstra, J. P., Jacobs, L., Zuerbig, P., Thijs, L., Ramirez-Torres, A., Heerspink, H. J. L., Lindhardt, M., Klein, R., Orchard, T., Porta, M., Bilous, R. W., Charturvedi, N., Rossing, P., Vlahou, A., Schepers, E., Glorieux, G., Mullen, W., ... Jankowski, J. (2017). Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney International Reports, 2(6), 1066-1075. https://doi.org/10.1016/j.ekir.2017.06.004

@article{253736bdf32f49daa08970e6212604c8,

title = "Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker",

abstract = "Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) toMethods: In analyses of 2087 individuals from 6 cohorts (46.4\% women; 73.5\% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100\%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2\%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P <0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30\% and 33\% and specificities of 82\% and 83\% (PDiscussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.",

keywords = "biomarker, chronic kidney disease, clinical science, glomerular filtration rate, peptidomics, proteomics, GLOMERULAR-FILTRATION-RATE, PROGRESSION, FIBROSIS, TRIAL, RECLASSIFICATION, MICROALBUMINURIA, CANDESARTAN, RETINOPATHY, PREVENTION, FIBRINOGEN",

author = "Claudia Pontillo and Zhen-Yu Zhang and Schanstra, \{Joost P.\} and Lotte Jacobs and Petra Zuerbig and Lutgarde Thijs and Adela Ramirez-Torres and Heerspink, \{Hiddo J. L.\} and Morten Lindhardt and Ronald Klein and Trevor Orchard and Massimo Porta and Bilous, \{Rudolf W.\} and Nishi Charturvedi and Peter Rossing and Antonia Vlahou and Eva Schepers and Griet Glorieux and William Mullen and Christian Delles and Peter Verhamme and Raymond Vanholder and Staessen, \{Jan A.\} and Harald Mischak and Joachim Jankowski",

year = "2017",

month = nov,

doi = "10.1016/j.ekir.2017.06.004",

language = "English",

volume = "2",

pages = "1066--1075",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "6",

}

Pontillo, C, Zhang, Z-Y, Schanstra, JP, Jacobs, L, Zuerbig, P, Thijs, L, Ramirez-Torres, A, Heerspink, HJL, Lindhardt, M, Klein, R, Orchard, T, Porta, M, Bilous, RW, Charturvedi, N, Rossing, P, Vlahou, A, Schepers, E, Glorieux, G, Mullen, W, Delles, C, Verhamme, P, Vanholder, R, Staessen, JA, Mischak, H & Jankowski, J 2017, 'Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker', Kidney International Reports, vol. 2, no. 6, pp. 1066-1075. https://doi.org/10.1016/j.ekir.2017.06.004

TY - JOUR

T1 - Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

AU - Pontillo, Claudia

AU - Zhang, Zhen-Yu

AU - Schanstra, Joost P.

AU - Jacobs, Lotte

AU - Zuerbig, Petra

AU - Thijs, Lutgarde

AU - Ramirez-Torres, Adela

AU - Heerspink, Hiddo J. L.

AU - Lindhardt, Morten

AU - Klein, Ronald

AU - Orchard, Trevor

AU - Porta, Massimo

AU - Bilous, Rudolf W.

AU - Charturvedi, Nishi

AU - Rossing, Peter

AU - Vlahou, Antonia

AU - Schepers, Eva

AU - Glorieux, Griet

AU - Mullen, William

AU - Delles, Christian

AU - Verhamme, Peter

AU - Vanholder, Raymond

AU - Staessen, Jan A.

AU - Mischak, Harald

AU - Jankowski, Joachim

PY - 2017/11

Y1 - 2017/11

N2 - Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) toMethods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P <0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (PDiscussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.

AB - Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) toMethods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P <0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (PDiscussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.

KW - biomarker

KW - chronic kidney disease

KW - clinical science

KW - glomerular filtration rate

KW - peptidomics

KW - proteomics

KW - GLOMERULAR-FILTRATION-RATE

KW - PROGRESSION

KW - FIBROSIS

KW - TRIAL

KW - RECLASSIFICATION

KW - MICROALBUMINURIA

KW - CANDESARTAN

KW - RETINOPATHY

KW - PREVENTION

KW - FIBRINOGEN

U2 - 10.1016/j.ekir.2017.06.004

DO - 10.1016/j.ekir.2017.06.004

M3 - Article

SN - 2468-0249

VL - 2

SP - 1066

EP - 1075

JO - Kidney International Reports

JF - Kidney International Reports

IS - 6

ER -

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Abstract

Keywords

Access to Document

Fingerprint

Cite this